Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective

Authors


  • Financial Disclosures
    Dr Toth is a member of the speakers bureau and consultant to the following: Abbott Laboratories, AstraZeneca, Merck, Merck Schering-Plough and Pfizer.

Peter P. Toth,
Sterling Rock Falls Clinic, 101 East Miller Road, Sterling, IL 61081, USA
Tel.: + 1 815 625 4790
Fax: + 1 815 626 5947
Email: peter.toth@srfc.com

Summary

Achieving adequate control of cardiovascular risk in type 2 diabetes mellitus (DM) is crucially important; however, the atherogenic dyslipidaemia (including low high-density lipoprotein cholesterol and hypertriglyceridaemia) typically encountered in type 2 DM is often managed inadequately. Evidence from the Fenofibrate Intervention and Event Lowering in Diabetes study suggests that fenofibrate reduces the risk of long-term macrovascular and microvascular type 2 diabetic complications, especially in patients demonstrating features of the metabolic syndrome. Fenofibrate represents a useful treatment option for controlling cardiovascular risk in type 2 diabetes patients in the community setting.

Ancillary